REG - OptiBiotix Health - Launch of LeanBiome in Muscletech

OptiBiotix HealthAnnouncement

15/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240115:nRSO5934Za&default-theme=true

RNS Number : 5934Z  OptiBiotix Health PLC  15 January 2024

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of LeanBiome® in Muscletech®

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare announces
the forthcoming launch of LeanBiome® in Muscletech®, one of the leading
sports nutrition brands in the industry and backed by America's No. 1 selling
sports supplement company (see About Us · MuscleTech
(https://www.muscletech.com/pages/about) ). The product is currently being
advertised on social media by the Company's partner ahead of online and
instore launches with multiple retailers in Sweden, France, Poland, Germany,
the Netherlands, Greece and the UK - see
https://www.stack3d.com/2024/01/muscletech-nitro-tech-ripped-europe.html
(https://www.stack3d.com/2024/01/muscletech-nitro-tech-ripped-europe.html)

 

Muscletech® is known as a leading brand in the science nutrition space
recognised for its research with scientific experts to identify and utilise
science backed ingredients in their products to bring unique benefits to
athletes and fitness enthusiasts around the world. LeanBiome® will be
incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder
designed to support athletes who want to lose fat and build lean muscle and
will be launched in Europe and the United Kingdom across multiple e-commerce
sites and distribution channels.

 

LeanBiome® is a scientifically formulated sports nutrition ingredient which
has been developed by OptiBiotix to support athletes seeking to increase lean
muscle mass and to change their body composition. LeanBiome® contains a
patented combination of fibres, prebiotics and minerals developed to increase
the microbiome diversity of athletes on a high protein diet. A diverse
microbiome is important in harvesting essential nutrients from the diet and
has been linked to improved health and wellbeing and increased resilience to
disease. Many researchers now believe that a diverse microbiome is an
essential factor in achieving physical fitness, which was previously thought
to be achievable solely through a healthy diet and regular exercise. This is
supported by the growing scientific evidence of a link between the microbiome
and athletic performance which suggest that optimizing an athletes gut
microbiome could improve and athletes stamina, lower inflammation, and support
physical fitness (Frontiers | Editorial: Nutrition to support gut health and
the microbiome in athletes (frontiersin.org)
(https://www.frontiersin.org/articles/10.3389/fnut.2023.1207543/full)

 

 

Stephen OHara, CEO of OptiBiotix Health plc commented: "We are very pleased to
announce the launch of LeanBiome® with such a well-known and internationally
respected sports brand such as Muscletech®. LeanBiome® has been formulated
to support anyone interested in improving their fitness for leisure or the
elite athlete. It is supported by multiple published clinical studies which
show it helps reduce body fat around the waist and hips, improving body
leanness whilst enhancing the diversity of the gut microbiome to improve
stamina and overall fitness.

 

"LeanBiome® is a unique product which is increasingly being recognised by
major sports brands as a key differentiator from existing products and has the
potential to have a major impact in the sports nutrition and health and
fitness markets."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)               Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBTMFTMTJBBBI